8-K: Myriad Genetics Reports Stable Q3 Amid Headwinds, Reaffirms 2025 Guidance

Myriad Genetics announced third quarter 2025 financial results, reporting stable revenue excluding headwinds and reaffirming its full-year 2025 financial guidance.

Summary

• Third quarter 2025 revenue was $205.7 million, a 4% decrease year-over-year, but flat when excluding $8.1 million in previously discussed headwinds.
• Total test volumes increased 3% year-over-year to 386,000 in Q3 2025.
• Hereditary cancer testing revenue grew 3% year-over-year, with volumes up 11%.
• Pharmacogenomics (GeneSight) revenue decreased 19% year-over-year to $38.7 million, primarily due to UnitedHealthcare's discontinuation of coverage.
• GAAP net loss for Q3 2025 was $27.4 million, or $0.29 per share, while adjusted EPS was $0.00.
• Adjusted EBITDA for Q3 2025 was $10.3 million.
• Cash flow provided by operations was $21.1 million in Q3 2025, with adjusted operating cash flow at $24.8 million.
• The company reiterated its full-year 2025 financial guidance, projecting revenue between $818 million and $828 million, adjusted EBITDA between $27 million and $33 million, and adjusted EPS between $(0.02) and $0.02.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While GAAP net loss persists and revenue saw a slight decline, the company achieved stable revenue performance when accounting for significant headwinds. Strong volume growth in hereditary cancer and pharmacogenomics, coupled with strategic collaborations and reaffirmed full-year guidance, indicates a resilient operational performance and a clear path forward despite challenges.

Positives

• Revenue was flat year-over-year when excluding $8.1 million in headwinds from UNH coverage discontinuation and European EndoPredict divestiture, consistent with management expectations.
• Total test volumes increased 3% year-over-year in Q3 2025.
• Hereditary cancer testing revenue grew 3% year-over-year, with volumes increasing 11% for MyRisk hereditary cancer test.
• Pharmacogenomics (GeneSight) test volume grew 8% year-over-year, showing ongoing improvement despite revenue impact from coverage changes.
• Gross margin was 69.9% in Q3 2025, described by management as 'among the best in the industry'.
• Adjusted operating expenses decreased $1.0 million year-over-year to $140.0 million, reflecting disciplined cost management.
• Cash flow provided by operations significantly improved to $21.1 million in Q3 2025, compared to $0.7 million in Q3 2024.
• Entered a strategic collaboration with SOPHiA GENETICS to develop a global liquid biopsy companion diagnostic (CDx) testing solution.
• Intends to commercially launch its first AI-enabled prostate cancer test in partnership with PATHOMIQ in the first half of 2026.
• Precise MRD test performance in oligometastatic clear-cell renal cell carcinoma (ccRCC) was highlighted in The Lancet Oncology, demonstrating ultrasensitive detection capabilities.
• Added F8 and FXN genes to its Foresight Universal Plus Panel, now including all conditions recommended by the American College of Medical Genetics and Genomics for prenatal screening.

Negatives

• Total revenue decreased 4% year-over-year to $205.7 million in Q3 2025.
• GAAP net loss was $27.4 million, or $0.29 per share, for Q3 2025.
• Pharmacogenomics (GeneSight) revenue decreased 19% year-over-year due to UnitedHealthcare's discontinuation of coverage.
• Tumor profiling revenue decreased 7% year-over-year, primarily due to the sale of the international EndoPredict business in August 2024.
• Prenatal testing volume decreased 3% year-over-year, largely driven by lower demand for SneakPeek.
• Adjusted EBITDA decreased to $10.3 million in Q3 2025 from $14.1 million in Q3 2024.
• Long-term debt increased to $119.5 million as of September 30, 2025, from $39.6 million at December 31, 2024, following a new term loan facility.

Risks

• Sales and profit margins of existing tests may decline.
• Inability to operate the business on a profitable basis.
• Failure to achieve certain revenue growth targets or generate sufficient revenue from existing or new tests.
• Risks related to recent changes in senior management and the successful implementation of the strategic plan.
• Changes in governmental or private insurers' coverage and reimbursement levels for tests, including UNH's coverage decisions for GeneSight.
• Increased competition and the development of new competing tests.
• Inability to develop or achieve commercial success for additional tests in a timely manner or at all.
• Inability to secure additional financing to fund the business on favorable terms, if needed.
• Failure to successfully develop new markets or channels for tests.
• Termination or inability to maintain licenses to the technology underlying tests on satisfactory terms.
• Delays or other problems with operating laboratory testing facilities.
• Public concern over genetic testing in general or the company's tests in particular.
• Regulatory requirements or enforcement changes in the United States and foreign countries, and changes in healthcare systems.
• Inability to obtain new corporate collaborations or licenses, or acquire/develop new technologies or businesses on satisfactory terms.
• Inability to successfully integrate and derive benefits from licensed, acquired, or developed technologies or businesses.
• Inaccurate projections or estimates about the potential market opportunity for current and future products.
• Inability to protect proprietary technologies or third-party infringement claims.
• Patent-infringement claims or challenges to the validity of patents.
• Changes in intellectual property laws covering tests, patents, or enforcement.
• Security breaches, loss of data, and other disruptions, including from cyberattacks.
• Inability to keep pace with rapid technology changes in the industry or properly leverage new technologies.
• Inability to comply with financial or operating covenants under credit or lending agreements.
• Inability to maintain effective disclosure controls and procedures and internal control over financial reporting.
• Current and future investigations, claims, or lawsuits, including derivative claims, product or professional liability claims, and risks related to insurance coverage limits.

Future Outlook

Myriad Genetics reiterated its full-year 2025 financial guidance, expecting revenue between $818 million and $828 million, gross margin between 69.5% and 70.0%, adjusted operating expenses between $562 million and $568 million, adjusted EBITDA between $27 million and $33 million, and adjusted EPS between $(0.02) and $0.02. The company intends to commercially launch its first AI-enabled prostate cancer test in partnership with PATHOMIQ in the first half of 2026. Strategic initiatives, including the collaboration with SOPHiA GENETICS, are expected to accelerate profitable growth by focusing on the Cancer Care Continuum, improve customer experience, gain market share, and reduce operating expenses as a percentage of revenue.

Management Comments

• "I am pleased with our solid results for the quarter, including stable year-over-year revenue performance excluding previously noted headwinds, and 13% year-over-year volume growth for our MyRisk hereditary cancer test."
• "Our disciplined execution also enabled our gross margin to be among the best in the industry and again yielded positive adjusted EBITDA."
• "We are executing on our updated strategy to accelerate profitable growth by focusing on the Cancer Care Continuum, including recently entering into a collaboration with SOPHiA GENETICS to provide Pharma customers with CDx development services using a leading liquid biopsy therapy selection assay."
• "We also made changes to our organizational structure and capital deployment, and expect these actions to support us in improving customer experience, gaining market share, and reducing operating expenses as a percentage of revenue going forward."

Industry Context

Myriad Genetics operates in the dynamic molecular diagnostic testing and precision medicine industry, which is characterized by rapid technological advancements and evolving payer coverage policies. The company's strategic collaboration with SOPHiA GENETICS for liquid biopsy companion diagnostics aligns with the growing trend towards personalized medicine and non-invasive testing in oncology. The planned launch of an AI-enabled prostate cancer test also reflects the industry's increasing adoption of artificial intelligence to enhance diagnostic accuracy and efficiency. The impact of UnitedHealthcare's discontinuation of coverage for GeneSight highlights the ongoing challenges and volatility related to reimbursement for multi-gene panel pharmacogenetic tests, a common hurdle for companies in this sector.

Comparison to Industry Standards

• The reported gross margin of 69.9% for Q3 2025 is stated by management as 'among the best in the industry', indicating strong operational efficiency relative to peers in molecular diagnostics.
• The addition of F8 and FXN genes to the Foresight Universal Plus Panel ensures the test now includes all conditions recommended by the American College of Medical Genetics and Genomics for prenatal screening, aligning with established industry guidelines for comprehensive prenatal care.

Stakeholder Impact

• Shareholders: Reaffirmed guidance and strategic initiatives may provide confidence in future performance, despite current GAAP losses.
• Customers: Organizational structure changes and strategic focus aim to improve customer experience.
• Employees: Strategic realignment costs, including severance, indicate some impact from organizational changes.

Next Steps

• Commercially launch the first AI-enabled prostate cancer test, in partnership with PATHOMIQ, in the first half of 2026.
• Continue executing on the updated strategy to accelerate profitable growth by focusing on the Cancer Care Continuum.
• Leverage the strategic collaboration with SOPHiA GENETICS for CDx development services, initially focusing on liquid biopsy applications.

Key Dates

Recommendation

Myriad Genetics delivered Q3 results that were largely in line with expectations, especially when adjusting for known headwinds. The company's strategic initiatives, including new collaborations and product pipeline developments (AI-enabled prostate cancer test, expanded prenatal panel), demonstrate a clear path for future growth. However, the continued GAAP net loss and the impact of payer coverage changes on key products like GeneSight present ongoing challenges. The reiteration of full-year guidance suggests stability, but significant upside catalysts are not immediately apparent. For a seasoned investor, holding the stock allows for observation of the execution of these strategic initiatives and their impact on profitability, while acknowledging the current mixed financial performance.

Keywords

Molecular Diagnostics, Precision Medicine, Genetic Testing, Hereditary Cancer, Pharmacogenomics, Prenatal Testing, Tumor Profiling, GeneSight, MyRisk, SOPHiA GENETICS, Liquid Biopsy, Companion Diagnostics, AI-enabled Prostate Cancer Test, PATHOMIQ, Precise MRD, Foresight Universal Plus Panel, SEC Filing, Earnings Report